Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & metho...

書誌詳細
主要な著者:	Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai
フォーマット:	論文
言語:	English
出版事項:	Taylor & Francis Group 2019-06-01
シリーズ:	CNS Oncology
主題:	bevacizumab glioblastoma glioma long term progression recurrence
オンライン･アクセス:	https://www.futuremedicine.com/doi/10.2217/cns-2019-0007

類似資料

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
著者:: Alissa Thomas, 等
出版事項: (2018-01-01)

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab
著者:: Josie Hayes, 等
出版事項: (2016-10-01)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
著者:: Patrick Roth, 等
出版事項: (2020-06-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
著者:: Bai X, 等
出版事項: (2024-11-01)

Bevacizumab in recurrent WHO grades II–III glioma
著者:: Soufyan Annakib, 等
出版事項: (2023-07-01)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
著者:: Joan Manel Gasent Blesa, 等
出版事項: (2012-12-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
著者:: D. R. Naskhletashvili, 等
出版事項: (2015-04-01)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
著者:: Mesti Tanja, 等
出版事項: (2015-03-01)

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
著者:: Moire Cuncannon, 等
出版事項: (2019-05-01)

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials
著者:: SiYao Wei, 等
出版事項: (2024-07-01)

Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab
著者:: Tomohiro Hosoya, 等
出版事項: (2024-11-01)

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
著者:: Mesti Tanja, 等
出版事項: (2018-11-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
著者:: N. García-Romero, 等
出版事項: (2020-06-01)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
著者:: Masahiro Nishikawa, 等
出版事項: (2021-03-01)

Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis
著者:: Zhaoyan Chen, 等
出版事項: (2024-05-01)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
著者:: Kathleen Van Dyk, 等
出版事項: (2022-06-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
著者:: Amy eBarone, 等
出版事項: (2013-04-01)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
著者:: Hiroyuki Tatekawa, 等
出版事項: (2021-03-01)

Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma
著者:: Rebecca Kassubek, 等
出版事項: (2023-05-01)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
著者:: Celina Bihan, 等
出版事項: (2012-09-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
著者:: Eudocia Q. Lee, 等
出版事項: (2019-10-01)

Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center
著者:: Margarida Simão-Rafael, 等
出版事項: (2023-12-01)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
著者:: Pia Banerjee, 等
出版事項: (2015-01-01)

Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
著者:: Ramon F. Barajas, 等
出版事項: (2016-10-01)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
著者:: George Ansstas, 等
出版事項: (2016-01-01)

Differential expression of the circadian clock network correlates with tumour progression in gliomas
著者:: Marina Petkovic, 等
出版事項: (2023-07-01)

Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
著者:: Barbara Castelli, 等
出版事項: (2023-09-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
著者:: Giovanni Luca Gravina, 等
出版事項: (2017-01-01)

Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis
著者:: Dong Liu, 等
出版事項: (2024-07-01)

Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
著者:: Barbara Castelli, 等
出版事項: (2024-02-01)

Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
著者:: Samy Ammari, 等
出版事項: (2021-07-01)

Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review
著者:: Oguz Ozel, 等
出版事項: (2016-08-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
著者:: Emil Lou, 等
出版事項: (2013-04-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
著者:: Seung Won Choi, 等
出版事項: (2018-05-01)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
著者:: Minjie Fu, 等
出版事項: (2023-06-01)

Circadian Alterations in a Murine Model of Hypothalamic Glioma
著者:: José M. Duhart, 等
出版事項: (2017-10-01)

Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines
著者:: Valerie J. Marallano, 等
出版事項: (2024-03-01)

Selected cytostatic drugs in the treatment of brain glioma – literature review
著者:: Jarosław Bała, 等
出版事項: (2021-11-01)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
著者:: Lei She, 等
出版事項: (2022-08-01)

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
著者:: Shanmu Jin, 等
出版事項: (2024-03-01)